chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (administered booster doses  stored in the refrigerator on 16Nov2021 (beyond the 30 use by date)) in a 76-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 027H21B, 032L20A and 032M20A) for COVID-19 vaccination. No Medical History information was reported. On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 16-Dec-2021 at 3:15 PM, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 16-Dec-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (administered booster doses  stored in the refrigerator on 16Nov2021 (beyond the 30 use by date)). On 16-Dec-2021, EXPIRED PRODUCT ADMINISTERED (administered booster doses  stored in the refrigerator on 16Nov2021 (beyond the 30 use by date)) had resolved. For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments. No Concomitant & treatment drug reported. Patient partial DOB reported-  02Ju1945.
Patient under 5 years old given pfizer covid-19 indicated for patients age 5-11 years old
Patient developed orthopnea, dyspnea on exertion, fatigue after receiving the Johnson & Johnson covid-19 vaccine. 1 week after the vaccine, she developed a profuse disseminated non-pruritic hyperpigmented rash that started on the hands and spread to the body, self-resolved.  She had 2 episodes of pericarditis within  3-4 months of vaccine administration, once in July 2021 and once in August 2021. She developed bilateral transudative pleural effusions necessitating therapeutic thoracentesis. she also has thrombocytopenia and normocytic anemia that was not present prior to vaccine. She has been now diagnosed with renal thrombotic microangiopathy confirmed on biopsy, now in renal failure requiring hemodialysis. All labs related to thrombotic microangiopathy work-up for causes such as SLE, TTP has been negative. The thrombotic microangiopathy seems to be related to the vaccine or a potential malignancy as an incidental 2cm pancreatic head mass has been found that may be malignant.
Widespread alopecia. Alopecia areata all over the entire body. Large patches of hair falling out on scalp, eyebrows, eyelashes, arms, legs, chest, etc. Rapid hair loss - diagnosed as alopecia areata/telogen effluvium - possible alopecia universalis onset. No prior history of chronic alopecia before vaccine doses 1 and 2.   Small patches developed on scalp after first shot, then after the second shot, a few days later, massive shedding all over body and face. Beard patches, and eyebrows thinning. Has progressed dramatically in the past several months.
Absence Seizures - Started in September 2015 and where reoccuring on a regular basis since then Grand Mal Seizures - Had first grand mal seizure on January 3, 2019 and had another one on February 14, 2019. Status Epilepticus - Happened on January 3rd in conjunction to her first grand mal seizure. Have yet to experience another status epilepticus at the moment. Delayed Speech - We have experienced this over the years and while being treated for her Status Epilepticus at Medical Center, we were told that she is very far behind in her speech and is currently speaking at a two year old level even though she is five years old.
This spontaneous report was received from a Registered Nurse regarding a 17 year old patient of unknown gender. The patient's pertinent medical history and concurrent conditions were not reported. On 13-APR-2016, the patient was vaccinated with VAQTA (50/1.0 U/ML (lot # L036449, expiry date 26-MAY-2017) 1 milliliter (ml)/once, intramuscular (Inappropriate schedule of vaccine administered). Concomitant medications were not reported. No adverse effects were reported. Product quality complaint (PQC) was not filed. Additional information has been requested.
Red, swollen left arm, no temperature, this was reported to public health by mom over the phone. No one saw the child. She was encouraged to call her doctor. No follow up was done.
Patient was COVID + on 11/7/20, but had fully recovered by the vaccination date 12/24/20.  The vaccination was unremarkable and the patient tolerated.  Approximately 72 hours post-vaccination, the patient developed widespread hives, that were most severe on her face and cheeks.  Patient did not have any respiratory effects.  Hives resolved within 24 hours with the use of oral diphenhydramine.  The patient is concerned with obtaining the second dose, whether it would be appropriate to receive the vaccine as long as appropriate medical interventions are available.
p/vax pt began sweating, feeling dizzy, faint;went home slept 12hr;today lt arm is very sore sl brain @ inj site;skin warm @ site;refer to MD;missed 3 days of work;
Shingles; This is a spontaneous report from a contactable consumer (patient) via Pfizer-sponsored program. A 59-year-old female patient received her first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) in Dec2020 at 12:00 at single dose in left arm for COVID-19 immunisation at the age of 59-year-old. Lot number was EJ1686. Medical history and concomitant medications were unknown. Patient received SHINGRIX in 2020 and shingles vaccine in 2011 (also reported in 2020), flu shot in 2020 (Sep2020 or Oct2020); all vaccines received for immunisation. On 12Jan2021, the patient developed Shingles; the patient did not visit the emergency room. The patient was due for the second dose of suspect vaccine on the 19Jan2021. The patient did not recover from the event.
Patient reported that had pain at injection site immediately and it has continued to this date.  Has some limited range of motion.  This occurred in his arm.  He reports that he tried to ignore it for awhile, then made an appointment with his doctor.  MRI was ordered by his doctor and is being done 12/27/12. Treatment is awaiting MRI reading.
Date of Admission 08/03/2021. Chief Complaint COVID + on 7/29/21, increased shortness of breath; placed on 4L NC in triage This is a 72-year-old Caucasian gentleman who presented to the hospital on August 3rd with complaints of shortness of breath after being diagnosed with COVID-19 4 days earlier.   The patient has a known history of COPD and states that he uses a trilogy machine at home but is not on oxygen on an around the clock basis.  The patient did ultimately require intubation but was extubated on August 8th.   He had some difficulties yesterday with oxygenation and was on BiPAP at 100% there was some concern that he was going to need re-intubation.  However, the patient status has improved somewhat today he is on Precedex to help control some of his agitation and restlessness and he is now been weaned to high-flow nasal cannula.  The patient is in the intensive care unit and is awake and alert to self and place but otherwise pleasantly confused.  He does not know the year nor the name of the president.  Result Title: Patient Death Performed By: RN on August 28, 2021 19:38 EDT Verified By: RN on August 28, 2021 19:38 EDT Encounter info: 3791927, DEL, Inpatient, 08/28/2021 - 08/29/2021 Examined patient. No spontaneous audible heart sounds, no spontaneous audible breath sounds, no corneal reflex, no pupil response. Patient expired at 1705 with family at bedside.
Member received vaccine on 5/9/05. On 5/18/05, patient started getting satellite lesions all over her body, face, neck, back, arms, scalp, and legs. Patient confirms she has been careful to keep the vaccine site covered at all times.
This spontaneous report as received from registered nurse refers to a male, child patient (age not further specified). Information on medical history was not reported. On 24-JUL-2013 the patient was vaccinated with M-M-R II (lot # not reported) injection shot, 0.5 ml (dose number, route, indication not reported). The nurse stated that as she was giving injection of M-M-R II to a patient, the patient flicked his arm and very last drops of injection shot out of needle and landed on patient's mom's forehead. It was also reported that patient probably moved the arm due to some pain or stinging. The outcome of the events was unknown. The reporter did not assessed the relationship between the therapy with M-M-R II and the adverse events. Product Quality Compliant (PQC) was not involved. This is one of the reports from the same source. Additional information has been requested.
5 mins after my dose I got dizzy, extreme hot flashes same as my pregnancy, I got home, I was severely nausea for a week and bedridden for 2-3 days. I told my therapist. I was great 8 years, got worst after the vaccine for mental health issue. Weird experience - It felt like I wasn't taking medication and now in a process of getting new medication. I was taking the same meds for 8 years, the meds felt like I built up resistance to it.
PRESENTED  IN OFFICE WITH C/O ITCHING AND RASH. ON AMOXIL SUSP FOR STREP SINCE 05/05/2006.ONSET OF RASH LAST PM.WATERY BLISTERS COVERING ENTIRE BODY.>50POX ON DAY 2 OF BREAKOUT
Patient was given MMR and Varicella on the 28th of Aug 2017 came in the 29th of Aug 2017 with the.
?Normal? post vaccination symptoms for a few days then long term fatigue.  Shortness of breath started within one week and has continued since late March.  Shortness of breath at rest and worse with exercise.
High fever, very swollen upper arm, unable to move x 1 day; resolving 2nd day;
Minimal change disease; This literature-non-study case was reported in a literature article and describes the occurrence of GLOMERULONEPHRITIS MINIMAL LESION (Minimal change disease) in a 72-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.      No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced GLOMERULONEPHRITIS MINIMAL LESION (Minimal change disease) (seriousness criterion medically significant). At the time of the report, GLOMERULONEPHRITIS MINIMAL LESION (Minimal change disease) outcome was unknown. Related    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Biopsy: glomerular disease Proven glomerular disease in patients recently vaccinated against SARS-CoV-2.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered GLOMERULONEPHRITIS MINIMAL LESION (Minimal change disease) to be related.    No Concomitant medications were reported. No Treatment information was reported. 28 patients were found with disease of de novo GN within native kidney biopsies and one patient with disease flare in an allograft  This is a literature non-study case concerning a 72-year-old male patient with no reported medical history, who experienced the unexpected serious events of Glomerulonephritis minimal lesion. The events was medically significant occurred on an unknown interval after receiving the second dose of mRNA-1273 COVID 19 Vaccine. Patients lab test showed Biopsy: glomerular disease. It was reported that the outcome of the event was unknown. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.   This case was linked to MOD-2022-539890, MOD-2022-539891, MOD-2022-539885, MOD-2022-539893, MOD-2022-539894, MOD-2022-539895, MOD-2022-539896, MOD-2022-539897, MOD-2022-539898, MOD-2022-539899, MOD-2022-539900, MOD-2022-539901, MOD-2022-539902, MOD-2022-539903.; Sender's Comments: This is a literature non-study case concerning a 72-year-old male patient with no reported medical history, who experienced the unexpected serious events of Glomerulonephritis minimal lesion. The events was medically significant occurred on an unknown interval after receiving the second dose of mRNA-1273 COVID 19 Vaccine. Patients lab test showed Biopsy: glomerular disease. It was reported that the outcome of the event was unknown. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.
Bell's Palsy; affected my self-confidence; This is a spontaneous report received from a contactable reporter (Consumer or other non HCP). The reporter is the patient.  A patient (no qualifiers provided) received BNT162b2 (BNT162B2), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: BELL'S PALSY (medically significant), outcome "unknown"; PSYCHIATRIC SYMPTOM (non-serious), outcome "unknown", described as "affected my self-confidence". The patient developed Bell's Palsy on the right side of the face after taking the Pfizer COVID vaccine. The patient's right eye still droops after taking the injection one year and three months ago. It has affected the patient's self-confidence and causes people to stare. The patient's ophthalmologist suggested to use a drop called Upneeq for special occasions that will help the eye not appear so diminished. These are expensive and the patient could not afford them. The patient have read that Bell's Palsy is a side effect of the vaccine.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Neurological feelings in legs and feet; tingling feelings; This is a spontaneous report from a contactable consumer (patient) and from Pfizer. A female patient of unspecified age received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Lot Number: Unknown), via an unspecified route on unspecified date as dose 1, single for covid-19 immunisation. The patient medical history and concomitant medications were not reported. On unspecified date, the patient experienced neurological feelings in legs and feet 3 or 4 days and tingly feelings. The outcome of the events was unknown.  Follow-up (11May2021): Follow-up attempts completed. No further information expected.
Swelling of left arm, redness, tenderness fever x 1day, ice, Tylenol.
Acute renal failure, admitted to the  hospital on 4/6/21.  Underlying source never identified, died on 4/9/21.
pt recvd vax; generalyzed measle rash p/ 1 wk of date of adm; low grade fever;
vomiting; Fever (high = 101.9) the day after; stomach ache; headache; lethargy; diarrhea; This is a spontaneous report received from a contactable reporter(s) (Pharmacist).  A 6 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), intramuscular, administered in leg left, administration date 27Jan2022 (Lot number: FL0007) at the age of 6 years as dose 2, 10 ug single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose Number: 1, Batch/Lot No: FK5618, Location of injection: Leg Left, Route of Administration: Intramuscular), administration date: 05Jan2022, when the patient was 6 years old, for COVID-19 Immunization. The following information was reported: VOMITING (non-serious) with onset 28Jan2022, outcome "recovering", described as "vomiting"; PYREXIA (non-serious) with onset 28Jan2022, outcome "recovering", described as "Fever (high = 101.9) the day after"; ABDOMINAL PAIN UPPER (non-serious) with onset 28Jan2022, outcome "recovering", described as "stomach ache"; HEADACHE (non-serious) with onset 28Jan2022, outcome "recovering", described as "headache"; LETHARGY (non-serious) with onset 28Jan2022, outcome "recovering", described as "lethargy"; DIARRHOEA (non-serious) with onset 28Jan2022, outcome "recovering", described as "diarrhea". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of vomiting, pyrexia, abdominal pain upper, headache, lethargy, diarrhoea.  Additional information: The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient does not receive any other medications within 2 weeks of vaccination. The patient was not diagnosed with COVID-19 prior to vaccination. The patient has not been tested for COVID-19 since the vaccination.  No follow-up attempts are possible. No further information is expected.
Face flush and hot Throat, chest burning Slight tightness in throat and chest  Took Benadryl and Pepcid Burning went away before taking benedril in about 45 min. Flush face remained about 2 hrs after taking Benadryl. Tightness in chest subsided after taking Benadryl. Continuing with Benadryl every 6 hrs for 5 days, Pepcid 2x/ day 5 days.
Extreme weakness and tiredness (do not want to get out of bed but did anyway, have to work...), pain, swelling  and redness at injection site continues 5 days after injection
Redness, itching and fever in arm where Td shot was given. Put on antibiotic, Prednisone and Zyrtec. Took 6 days to get better but still have some redness as of today 10-25-07.
Information has been received from a nurse concerning an elderly patient who on 18-NOV-2010 was vaccinated with a dose of PNEUMOVAX 23 (Lot # not provided). It was reported that the patient experienced and injection site reaction. The patient experienced radiating pain and lack of functionality of the arm. The patient called 911 and was evaluated by paramedics. No treatment was reported by the paramedics. No hospitalization. The patient will be scheduled for an office evaluation. At the time of this report, the patient's outcome was unknown. Follow up information has been received from the nurse concerning the 81 year old retired female patient with no illness at time of vaccination and with hypersensitivity to prednisone (caused illness), intolerance to many medicines and many skin allergies (including perfumes) who on 18-NOV-2010 at 11:42 was vaccinated intramuscularly in the left deltoid with a first dose of PNEUMOVAX 23 (Lot # 667271/0880Z). The nurse reported that started hurting within a couple of hours, progressed to extreme pain. No redness or swelling at the site. The patient called to emergency medical services that evening but patient did not go to the hospital. Patient could not use the arm, unable to move it due to pain, level 10. The nurse stated that gradually the patient improved over 4 to 5 days (approximately on 23-NOV-2010). No further information is available.
This spontaneous report was received from a certified medical assistant concerning a multiple unspecified number of patients of unknown age and gender. The patients' medical history, concurrent conditions and concomitant medications were not reported. On unspecified dates, the patients were vaccinated with improperly stored doses of VAQTA lot numbers: K026529, L009445, L018499, L028666, K018181, L023936, L045713, M009377, L015460, M018644, M022924, M033611 and M039202 (strength, dose, route of administration and expiration dates were not reported) for prophylaxis. It was reported that all vaccines involved in temperature excursion were vaccines for children (VFC). The administered doses of VAQTA were exposed to temperature excursions between 26° (unspecified units) (lowest) and 75° (unspecified units) (highest) for 12 hours each day, from 15-DEC-2015 to 31-MAR-2017. No adverse effects were reported. A digital data logger was involved. This is one of several reports received from the same source. Additional information has been requested.; Sender's Comments: US-009507513-1703USA007467: US-009507513-1705USA001209: US-009507513-1705USA001210: US-009507513-1705USA001211: US-009507513-1705USA001212:
Left thigh cellulitis around injection site. Treated with 2 doses IM Ceftriaxone and followed by 10 days oral antibiotic Cephalexin.
11/15/2022 in the morning, fatigue and stuffiness that felt like an oncoming sinus infection. These got worse until 12/19/2022 when I went to the emergency room. Fatigue, coughing, heavy sweats. I was constantly sleeping, up to 20 hours a day. Uncontrollable shakes and pain in sides. I was admitted to the hospital that day. Doctor in ER did blood work and ordered X-rays. Blood work was positive for COVID-19. The X-rays revealed a kidney stone and kidneys were not functioning in normal range. There was also a Urinary Tract Infection. Loss of taste and smell with loss of appetite. During the hospital stay, there were blood pressure problems. Participant felt better around 4th day, 12/23. By day five, 12/24, I could sit up, blood pressure was back in range as was kidney function. Vision issues also happening. I was discharged from the hospital at that time with an antibiotic cefuroxime to treat the UTI. Fatigue lingers. According to optometrist visited on 12/27, vision issue was due to blood pressure spike and should return to normal with time and hydration. Retinal Cotton Wool Spots. Fatigue and loss of appetite lingers with sporadic headaches.
previous wasp stings turning into welps once a week since the injection. continues to have allergic type reaction weekly. redness, swelling, itching, and inflammation of skin. this problem did not occur ever prior to the injection. all other medications/variables are the same.